Brief Motivational Intervention (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users

Who May Qualify: - Continuous treatment (at least once daily) with BZD/Z for at least 6 months, after verification of 6 months' supply. - Signed willing to sign a consent form - Patient able to understand the survey and complete a questionnaire in French. - Affiliation with the French social security system Who Should NOT Join This Trial: - Concomitant treatment with: - The following oral antipsychotics: risperidone, olanzapine, aripiprazole, quetiapine, clozapine, haloperidol, flupentixol, pimozide, chlorpromazine, sulpiride, zuclopenthixol, loxapine, cyamemazine (\>100mg/D), sulpiride (\>150mg/D), - Injectable medium- and long-acting antipsychotics - Thymoregulatory treatment with lithium - Treatments for alcohol use disorders: baclofen, nalmefene, naltrexone, acamprosate, disulfiram - Opiate substitution treatments: buprenorphine, methadone - Anti-epileptic drugs - History of convulsions or epilepsy - History of gabaergic withdrawal accidents: delirium tremens, confusional syndrome requiring specialist treatment (hospitalisation, specialist consultation), epileptic seizures, etc. - Patients suffering from cancer - Persons referred to in articles L1121-5 to L1121-8 of the French Public Health Code (corresponding to all protected persons: pregnant women, women in childbirth, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to a legal protection measure). Always talk to your doctor about whether this trial is right for you.